References
- Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: Deconstructing motor neuron degeneration. Neurology. 2009;73:805–11.
- Goyal NA, Berry JD, Windebank A, Nathan P, Maragakis NJ, Berg LH, et al. Addressing heterogeneity in ALS clinical trials. Muscle Nerve. 2020;62:156–66.
- Moore DH, Katz JS, Miller RG. A review of clinical trial designs in amyotrophic lateral sclerosis. Neurodegen Dis Manage. 2011;1:481–90.
- McDermott CJ. Clinical trials in amyotrophic lateral sclerosis. Curr Opin Neurol. 2019;32:758–63.
- van Eijk RPA, Westeneng HJ, Nikolakopoulos S, Verhagen IE, van Es MA, Eijkemans MIC, et al. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. 2019;92:e451–e460.
- Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2005;77:390–2.
- Czaplinski A, Yen AA, Appel SH. Amyotrophic lateral sclerosis: early predictors of prolonged survival. J Neurol. 2006;253:1428–36.
- Berry JD, Taylor AA, Beaulieu D, Meng L, Bian A, Andrews J, et al. Improved stratification of ALS clinical trials using predicted survival. Ann Clin Transl Neurol. 2018; 5:474–85.
- Westeneng H-J, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol.2018;17:423–33.
- Andrews JA, Berry JD, Baloh RH, Carberry N, Cudkowicz ME, Dedi B, et al. Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: challenges and opportunities. Muscle Nerve. 2020;62:182–6.
- Norris SP, Likanje MN, Andrews JA. Amyotrophic lateral sclerosis: update on clinical management. Curr Opin Neurol. 2020;33:641–8.
- De Marchi F, Cantello R, Ambrosini S, Mazzini L, CANPALS Study Group. Telemedicine and technological devices for amyotrophic lateral sclerosis in the era of COVID-19. Neurol Sci. 2020;41:1365–7. Jun
- Capozzo R, Zoccolella S, Musio M, Barone R, Accogli M, Logroscino G. Telemedicine is a useful tool to deliver care to patients with amyotrophic lateral sclerosis during COVID-19 pandemic: results from Southern Italy. Amyotroph Lateral Scler Frontotemporal Degener 2020;21:542–548.
- Vasta R, Moglia C, D'Ovidio F, Di Pede F, De Mattei F, Cabras S, et al. Telemedicine for patients with amyotrophic lateral sclerosis during COVID-19 pandemic: an Italian ALS referral center experience. Amyotroph Lateral Scler Frontotemporal Degener 2021;22:308–311.
- Govindarajan R, Berry JD, Paganoni S, Pulley MT, Simmons Z. Optimizing telemedicine to facilitate amyotrophic lateral sclerosis clinical trials. Muscle Nerve. 2020;62:321–6.
- Zach N, Ennist DL, Taylor AA, Alon H, Sherman A, Kueffner R, et al. Being PRO-ACTive - What can a clinical trial database reveal about ALS? Neurotherapeutics. 2015;12:417–23.
- Shefner JM, Cudkowicz ME, Hardiman O, Cockroft BM, Lee JH, Malik FI, VITALITY-ALS Study Group, et al. A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:584–94.
- Traxinger K, Kelly C, Johnson BA, Lyles RH, Glass JD. Prognosis and epidemiology of amyotrophic lateral sclerosis: Analysis of a clinic population, 1997-2011. Neurol Clin Pract. 2013;3:313–20.
- Breiman L 2001. Random Forests. Machine Learning Journal 45:5-32. Available at Berkeley Statistic Department website: https://www.stat.berkeley.edu/∼breiman/randomforest2001.pdf
- Moons KGM, Wolff RF, Riley RD, Whiting PF, Westwood M, Collins GS, et al. PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration. Ann Intern Med. 2019;170:W1.
- Friedman JH. Greedy function approximation: a gradient boosting machine. Ann. Stat 2001;29:1189–232.
- Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014;35:1925–31.
- Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statist Med. 1996;15:361–87.
- Crowson CS, Atkinson EJ, Therneau TM. Assessing calibration of prognostic risk scores. Stat Methods Med Res. 2016;25:1692–706.
- Steyerberg EW. 2019. Chapter 17: Validation of prediction models. In: Clinical prediction clinical prediction models: a practical approach to development, validation, and updating. Cham, Switzerland: Springer Nature, 299–311.
- Wickham, H. 2019. Package ‘tidyverse’. Retrieved from The Comprehensive R Archive Network website: https://cran.r-project.org/web/packages/tidyverse/tidyverse.pdf
- Ishwaran H, Kogalur UB. 2020. Package ‘randomForestSRC’. Retrieved from The Comprehensive R Archive Network website: https://cran.r-project.org/web/packages/randomForestSRC/randomForestSRC.pdf
- Ridgeway G, Edwards D, Kriegler B, Schroedl S, Southworth H. 2020. Package ‘gbm’. Retrieved from The Comprehensive R Archive Network website: https://cran.r-project.org/web/packages/gbm/gbm.pdf
- Therneau T. 2020. Package ‘survival’. Retrieved from The Comprehensive R Archive Network website: https://cran.r-project.org/web/packages/survival/survival.pdf
- Heagerty PJ. 2015. Package ‘survivalROC’. Retrieved from The Comprehensive R Archive Network website: https://cran.r-project.org/web/packages/survivalROC/survivalROC.pdf
- Kassambara A. 2020. Package ‘survminer’. Retrieved from The Comprehensive R Archive Network website: https://cran.r-project.org/web/packages/survminer/survminer.pdf
- FDA. 2019. Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment. Guidance for Industry. Retrieved May 1, 2020 from FDA website: https://www.fda.gov/media/130964/download
- Shmueli G. To explain or to predict? Statist Sci. 2010;25:289–310.